| Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience S Park, S Grabar, C Kelaidi, O Beyne-Rauzy, F Picard, V Bardet, ... Blood, The Journal of the American Society of Hematology 111 (2), 574-582, 2008 | 388 | 2008 |
| Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia S Park, N Chapuis, J Tamburini, V Bardet, P Cornillet-Lefebvre, L Willems, ... haematologica 95 (5), 819, 2010 | 365 | 2010 |
| Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia P Sujobert, V Bardet, P Cornillet-Lefebvre, JS Hayflick, N Prie, F Verdier, ... Blood 106 (3), 1063-1066, 2005 | 350 | 2005 |
| Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia L Willems, N Jacque, A Jacquel, N Neveux, T Trovati Maciel, M Lambert, ... Blood, The Journal of the American Society of Hematology 122 (20), 3521-3532, 2013 | 326 | 2013 |
| Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid … J Tamburini, N Chapuis, V Bardet, S Park, P Sujobert, L Willems, N Ifrah, ... Blood, The Journal of the American Society of Hematology 111 (1), 379-382, 2008 | 318 | 2008 |
| Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia D Selimoglu-Buet, O Wagner-Ballon, V Saada, V Bardet, R Itzykson, ... Blood, The Journal of the American Society of Hematology 125 (23), 3618-3626, 2015 | 261 | 2015 |
| The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation AS Green, N Chapuis, T Trovati Maciel, L Willems, M Lambert, C Arnoult, ... Blood, The Journal of the American Society of Hematology 116 (20), 4262-4273, 2010 | 244 | 2010 |
| PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML S Park, N Chapuis, V Bardet, J Tamburini, N Gallay, L Willems, ZA Knight, ... Leukemia 22 (9), 1698-1706, 2008 | 242 | 2008 |
| Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia J Tamburini, AS Green, V Bardet, N Chapuis, S Park, L Willems, ... Blood, The Journal of the American Society of Hematology 114 (8), 1618-1627, 2009 | 230 | 2009 |
| High levels of CD34+ CD38low/− CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang … F Vergez, AS Green, J Tamburini, JE Sarry, B Gaillard, ... haematologica 96 (12), 1792, 2011 | 215 | 2011 |
| Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia N Chapuis, J Tamburini, AS Green, C Vignon, V Bardet, A Neyret, ... Clinical Cancer Research 16 (22), 5424-5435, 2010 | 208 | 2010 |
| A critical role for Lyn in acute myeloid leukemia C Dos Santos, C Demur, V Bardet, N Prade-Houdellier, B Payrastre, ... Blood, The Journal of the American Society of Hematology 111 (4), 2269-2279, 2008 | 183 | 2008 |
| Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients J Tamburini, C Elie, V Bardet, N Chapuis, S Park, P Broët, ... Blood, The Journal of the American Society of Hematology 110 (3), 1025-1028, 2007 | 174 | 2007 |
| Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody N Chapuis, J Tamburini, P Cornillet-Lefebvre, L Gillot, V Bardet, L Willems, ... haematologica 95 (3), 415, 2010 | 158 | 2010 |
| Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies N Chapuis, J Tamburini, AS Green, L Willems, V Bardet, S Park, ... Leukemia 24 (10), 1686-1699, 2010 | 132 | 2010 |
| How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? F Garnache-Ottou, C Vidal, S Biichlé, F Renosi, E Poret, M Pagadoy, ... Blood advances 3 (24), 4238-4251, 2019 | 114 | 2019 |
| Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes S Mathis, N Chapuis, C Debord, A Rouquette, I Radford-Weiss, S Park, ... Leukemia 27 (10), 1981-1987, 2013 | 106 | 2013 |
| IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia N Chapuis, S Park, L Leotoing, J Tamburini, F Verdier, V Bardet, ... Blood, The Journal of the American Society of Hematology 116 (20), 4240-4250, 2010 | 102 | 2010 |
| Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-β signaling at the bipotent erythro-megakaryocytic progenitor stage V Randrianarison-Huetz, B Laurent, V Bardet, GC Blobe, F Huetz, ... Blood, The Journal of the American Society of Hematology 115 (14), 2784-2795, 2010 | 93 | 2010 |
| Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry V Bardet, J Tamburini, N Ifrah, F Dreyfus, P Mayeux, D Bouscary, ... Haematologica 91 (6), 757-764, 2006 | 85 | 2006 |
